RAPID GENE Trial successfully utilizes point-of-care diagnostics for personalized antiplatelet medication

摘要

A new trial, conducted by researchers from the University of Ottawa Heart Institute (ON, Canada) has demonstrated a new point-of-care genetic test to successfully assess the appropriate drug therapy for patients after percutaneous coronary intervention (PCI). The cheek swab Spartan RX CYP2C19 bedside DNA test identifies patients who carry the CYP2C19*2 allele, a result that is then used to determine the appropriate antiplatelet therapy for the patient. The CYP2C19*2 allele is associated with increased rates of major adverse events in patients who undergo PCI and are prescribed the standard Plavix~R (clopi-dogrel) antiplatelet therapy. However, assessment of appropriate pharmacoge-netic strategies is currently limited by a lack of bedside genetic tests.